(CNTA) Centessa Pharmaceuticals plc BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(CNTA) Centessa Pharmaceuticals plc Complete Analysis Pack
Unlock Strategic Clarity
This Centessa Pharmaceuticals plc BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio review. The content on this page is a real preview of the analysis, not just marketing text, so you can see the format and substance before buying. Purchase the full version to get the complete ready-to-use report.
Stars
No approved commercial product
As of end-2025, Centessa Pharmaceuticals plc remained a clinical-stage Company with no approved commercial product, so it has no asset with proven high market share. In BCG terms, there is no true Star yet. The Company reported no product revenue in 2025, and its value still depends on pipeline progress and clinical readouts, not marketed sales.
0 disclosed product revenue
Centessa Pharmaceuticals plc reported $0 disclosed product revenue, so its value still depends on R&D pipeline progress, not sales. Without a marketed product or revenue base, no franchise can be called a market leader. That leaves the Star bucket empty for now.
Lixivaptan is Phase III only
Lixivaptan is Centessa Pharmaceuticals plc’s most advanced asset, but it is still in Phase III for ADPKD, so it has no commercial share yet. ADPKD affects roughly 1 in 4,000 to 1 in 10,000 people, but Phase III only signals late-stage promise, not sales. It is a future Star candidate, not a current one.
SerpinPC is Phase IIa only
SerpinPC is still in Phase IIa for hemophilia A and B, so it has clinical promise but no approved-market sales in 2025. That keeps SerpinPC outside the Star bucket in Centessa Pharmaceuticals plc’s BCG Matrix, because Stars need both high growth and a market position. In 2025, it remains a pipeline asset, not a cash engine.
- Phase IIa only
- No approved market yet
- Not a 2025 Star
LB101, LB201, ZF874, MGX292, OX2R, CBS001, CBS004 are early stage
LB101, LB201, ZF874, MGX292, OX2R, CBS001, and CBS004 are early-stage Centessa Pharmaceuticals plc assets in proof-of-concept, Phase I, or precommercial work, so their current market share is 0. They are pipeline bets, not Stars, because sales have not started yet.
For Centessa Pharmaceuticals plc, these programs matter for future value, but they still carry clinical and funding risk; until data readouts and approvals land, they stay development assets.
- Zero revenue today
- High clinical risk
- Potential large markets
- No current share
Centessa Has No BCG Stars Yet—All Value Hangs on Future Readouts
Centessa Pharmaceuticals plc has no Stars in its BCG Matrix as of end-2025. It reported $0 product revenue in 2025, so no asset has a proven market share yet.
| Asset | 2025 status | BCG view |
|---|---|---|
| Lixivaptan | Phase III | Future Star only |
| SerpinPC | Phase IIa | Pipeline, not Star |
| Other programs | Precommercial | No share |
The Company’s value still depends on clinical readouts, approvals, and future sales, not current revenue. Until one program wins market share, the Star bucket stays empty.
What is included in the product
Detailed Word Document
Centessa Pharmaceuticals plc BCG Matrix pinpoints pipeline assets to invest in, hold, or divest.
Editable Excel File
One-page Centessa Pharmaceuticals plc BCG Matrix that simplifies portfolio decisions at a glance
Reference Sources
Provides a clear, traceable source trail for Centessa Pharmaceuticals plc, strengthening credibility and speeding investor due diligence.
Cash Cows
No mature revenue franchise
Centessa Pharmaceuticals plc has no approved product and no revenue franchise in a mature market, so it does not have a true Cash Cow. Cash Cows need high share and low growth, but end-2025 Centessa was still a clinical-stage company, not a commercial one. The quadrant stays empty, with no product sales to generate stable cash flow.
0 marketed drugs
Centessa Pharmaceuticals plc has 0 marketed drugs, so it has no stable product stream to generate surplus cash. In its latest annual filing, product revenue was still $0, while the company kept funding clinical trials and R&D. That means there is nothing to milk as a Cash Cow; cash is being consumed, not harvested.
No disclosed recurring sales base
Centessa Pharmaceuticals plc reported no recurring product sales in its latest filings, so there is no stable commercial cash engine to classify as a Cash Cow. As a clinical-stage biotech, its economics still depend on financing and milestone events, not operating sales, which fits a high-burn, pre-revenue profile.
No patent-expiry harvest asset
Centessa Pharmaceuticals plc has no Cash Cow asset yet, because Cash Cows need a proven, revenue-generating product with mature margins.
By end-2025, none of Centessa Pharmaceuticals plc's programs had reached harvest mode, so the portfolio still sits in the development stage, not the cash-generation stage.
This means no patent-expiry tail, no steady operating cash flow, and no established brand to fund growth internally.
- No approved, mature asset yet
- No 2025 harvest-stage program
- No patent-expiry cash flow
No low-growth high-share unit
Centessa Pharmaceuticals plc has no low-growth, high-share Cash Cow because it is still a clinical-stage company with no mature commercial franchise. In its latest filings, it remained pre-revenue, so the portfolio is still funded by capital markets and R&D spending, not by steady operating cash flow.
- No mature, high-share product unit
- Still dependent on pipeline success
- No Cash Cow to fund growth
Centessa Has No Cash Cow in 2025/2026—Still Pre-Revenue
Centessa Pharmaceuticals plc has no Cash Cow in 2025/2026 because it remains pre-revenue and clinical-stage. Product revenue was $0, and the company still funded R&D and trials instead of generating stable operating cash. With no approved drug, no mature franchise, and no low-growth market share, the Cash Cow quadrant stays empty.
| Metric | 2025/2026 |
|---|---|
| Product revenue | $0 |
| Marketed drugs | 0 |
| Cash Cow status | None |
Preview the Actual Deliverable
Centessa Pharmaceuticals plc Reference Sources
The Centessa Pharmaceuticals plc BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No sample pages, no placeholders—just the full, professionally formatted file. Download it instantly and use it for analysis, reporting, or presentation right away.
Dogs
No legacy commercial brand
Centessa Pharmaceuticals plc has no legacy commercial brand, so it does not fit the classic Dog profile of an old, low-share product in a stagnant market. As of 2025/2026, it still had 0 marketed drugs and remained a clinical-stage company. That means the portfolio is early, not mature, and its value depends on pipeline progress, not brand decline.
No divested product line
Centessa Pharmaceuticals plc had 0 marketed products in FY2025, so there is no disclosed commercial line that looks obsolete or cash-trapping. The mix stays centered on current clinical assets, not legacy sales. That means no clear Dog asset is visible in the portfolio.
With no product revenue to divest, the BCG "Dog" bucket is effectively empty for Centessa Pharmaceuticals plc.
No mature low-growth franchise
Centessa Pharmaceuticals plc has no mature low-growth franchise to classify as a Dog. Its pipeline is still in development, with no commercial revenue in 2025 and a market value around $1.6 billion in mid-2026, so it has not yet reached a low-share, low-growth stage. In BCG terms, the company has not accumulated a Dog bucket.
No break-even underperformer
Centessa Pharmaceuticals plc has no marketed asset that is merely breaking even, so the Dogs label does not fit. Its value is still tied to clinical-stage programs, not steady cash generation, and that keeps the portfolio in the high-risk, high-upside bucket rather than a low-return underperformer.
- No marketed asset
- No break-even cash flow
- Value remains clinical-stage
- So, not a Dog
The key test is simple: without a commercial product and recurring operating profit, there is no mature asset to classify as a Dog.
No clear liquidation candidate
Centessa Pharmaceuticals plc does not look like a clear Dog at end-2025. Its assets are still in testing, not harvest mode: seralutinib was in Phase 3 for pulmonary arterial hypertension, and ORX750 and other programs were still earlier-stage. That means the pipeline is being funded for data readouts, not stripped for sale.
- Phase 3 asset still advancing
- Early programs not yet monetized
- No clear divestiture signal
Centessa’s Dog Bucket Is Empty in FY2025/2026
Centessa Pharmaceuticals plc has no clear Dog in FY2025/2026. It had 0 marketed products and 0 product revenue, while seralutinib was still in Phase 3 and ORX750 remained clinical-stage. With no mature, low-share cash drain, the Dog bucket is effectively empty.
| Metric | FY2025/FY2026 |
|---|---|
| Marketed products | 0 |
| Product revenue | 0 |
| Lead assets | Phase 3 / early-stage |
Question Marks
Lixivaptan Phase III, ADPKD
Lixivaptan is Centessa Pharmaceuticals plc’s most advanced asset and its clearest near-term value driver. ADPKD affects about 12.4 million people worldwide, and the U.S. market is still small because the only approved drug, tolvaptan, serves a limited share. Lixivaptan has zero commercial share now, but a phase III win could move it from Question Mark toward Star status.
SerpinPC Phase IIa, hemophilia A and B
SerpinPC sits in a large, unmet-need niche: hemophilia A affects about 1 in 5,000 male births and hemophilia B about 1 in 25,000, with lifelong bleed risk and high treatment costs. Phase IIa means market share is still unproven, but strong efficacy and safety could open both rare-disease markets. That profile fits a classic Question Mark.
LB101 and LB201, PD-L1xCD47 and PD-L1xCD3 LockBodies
LB101 and LB201, the PD-L1xCD47 and PD-L1xCD3 LockBodies, are true question marks: novel oncology immune-engagers in clinical proof-of-concept, with high-growth biology but no Centessa Pharmaceuticals plc oncology sales base. Their value depends on clear efficacy and tolerability signals, because a weak safety readout can end the story fast. Until then, they stay high-upside, high-risk pipeline assets.
ZF874 Phase I, alpha-1-antitrypsin deficiency
ZF874 is still in Phase I for alpha-1-antitrypsin deficiency, so it has no commercial revenue or market share yet. In Centessa Pharmaceuticals plc’s BCG matrix, that makes it a clear Question Mark: high scientific and disease-specific upside, but no proven sales engine. Alpha-1-antitrypsin deficiency affects about 1 in 2,500 to 1 in 5,000 people of European ancestry, so the addressable niche is real but still narrow.
- Phase I only; no sales yet
- Genetically defined rare disease
- Commercial share: zero
- High upside, high execution risk
MGX292, OX2R agonists, CBS001, CBS004
MGX292, OX2R agonists, CBS001, and CBS004 are early clinical Question Marks: they sit in pulmonary hypertension, narcolepsy type 1, fibrosis, and autoimmune disease, but none has market share or approved sales yet.
The upside is large because each targets a high-value niche with strong unmet need, but the data are still too early to prove durable demand or pricing power.
- High-risk, high-upside pipeline assets
- No market share yet
- Need clinical data to justify spend
Centessa’s Pipeline: High-Risk, High-Upside Question Marks
Centessa Pharmaceuticals plc’s Question Marks are all pre-revenue assets with zero commercial share, but each has a clear shot at value if late-stage data hold. Lixivaptan is the closest to scale; SerpinPC, LB101, LB201, ZF874, MGX292, OX2R agonists, CBS001, and CBS004 remain high-risk, high-upside bets in rare or hard-to-treat diseases.
| Asset | Stage | Status |
|---|---|---|
| Lixivaptan | Phase III | Zero share now |
| SerpinPC | Phase IIa | Question Mark |
| LB101/LB201 | Clinical POC | High risk |
| ZF874 | Phase I | No revenue |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.